These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12736484)

  • 41. Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.
    van Hunnik A; Lau DH; Zeemering S; Kuiper M; Verheule S; Schotten U
    Heart Rhythm; 2016 Apr; 13(4):964-72. PubMed ID: 26681610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atrial fibrillation begets atrial fibrillation in the pulmonary veins on the impact of atrial fibrillation on the electrophysiological properties of the pulmonary veins in humans.
    Rostock T; Steven D; Lutomsky B; Servatius H; Drewitz I; Klemm H; Müllerleile K; Ventura R; Meinertz T; Willems S
    J Am Coll Cardiol; 2008 Jun; 51(22):2153-60. PubMed ID: 18510963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart.
    Hodess AB; Follansbee WP; Spear JF; Moore EN
    J Cardiovasc Pharmacol; 1979; 1(4):427-39. PubMed ID: 94620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Electrophysiological effect of verapamil on human atrium].
    Inoue M; Inoue D; Omori I; Shirayama T; Yamahara Y; Asayama J; Katsume H; Nakagawa M
    Kokyu To Junkan; 1991 Sep; 39(9):891-7. PubMed ID: 1749867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atrial electrophysiological features in patients with Wolff-Parkinson-White and atrial fibrillation: absence of rate adaptation of intraatrial conduction time parameters.
    Riccardi R; Gaita F; Giustetto C; Gardiol S
    Pacing Clin Electrophysiol; 1997 May; 20(5 Pt 1):1318-27. PubMed ID: 9170133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of cibenzoline on atrial vulnerability and value of electrophysiological methods in the treatment of paroxysmal atrial fibrillation].
    Kühlkamp V; Ickrath O; Seipel L
    Z Kardiol; 1990 Aug; 79(8):541-6. PubMed ID: 2220012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation.
    Kofune T; Watanabe I; Okubo K; Okumura Y; Masaki R; Shindo A; Saito S
    Pacing Clin Electrophysiol; 2005 May; 28(5):391-6. PubMed ID: 15869670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide.
    Wang Z; Feng J; Nattel S
    J Am Coll Cardiol; 1995 Jul; 26(1):277-86. PubMed ID: 7797763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of intravenous flecainide on atrial vulnerability in man.
    Pop T; Treese N
    Drugs; 1985; 29 Suppl 4():1-6. PubMed ID: 4006774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation.
    Kalifa J; Bernard M; Gout B; Bril A; Cozma D; Laurent P; Chalvidan T; Deharo JC; Djiane P; Cozzone P; Maixent JM
    Cardiovasc Drugs Ther; 2007 Feb; 21(1):47-53. PubMed ID: 17356910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute vagal modulation of electrophysiology of the atrial and pulmonary veins increases vulnerability to atrial fibrillation.
    Oliveira M; da Silva MN; Geraldes V; Xavier R; Laranjo S; Silva V; Postolache G; Ferreira R; Rocha I
    Exp Physiol; 2011 Feb; 96(2):125-33. PubMed ID: 20952490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electrophysiological properties of the human atrium in atrial fibrillation.
    Shimizu A; Centurion OA
    Cardiovasc Res; 2002 May; 54(2):302-14. PubMed ID: 12062336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
    Minami T; Isomoto S; Nakao K; Komiya N; Fukae S; Centurion OA; Yano K
    Pacing Clin Electrophysiol; 2004 Feb; 27(2):212-7. PubMed ID: 14764172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of flecainide on ectopic atrial automaticity and conduction.
    Windle JR; Witt RC; Rozanski GJ
    Circulation; 1993 Oct; 88(4 Pt 1):1878-84. PubMed ID: 8403333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Acute electrophysiological modulation of the atria and pulmonary veins: effects of sympathetic and parasympathetic interaction on atrial fibrillation inducibility].
    Oliveira M; Postolache G; Geraldes V; Silva V; Laranjo S; Tavares C; da Silva MN; Ferreira R; Rocha I
    Rev Port Cardiol; 2012 Mar; 31(3):215-23. PubMed ID: 22326990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation.
    Morillo CA; Klein GJ; Jones DL; Guiraudon CM
    Circulation; 1995 Mar; 91(5):1588-95. PubMed ID: 7867201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atrial vulnerability in patients with paroxysmal "lone" atrial fibrillation.
    Zimmermann M; Adamec R; Metzger J
    Pacing Clin Electrophysiol; 1998 Oct; 21(10):1949-58. PubMed ID: 9793092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent.
    Frommeyer G; Sterneberg M; Dechering DG; Kaese S; Bögeholz N; Pott C; Fehr M; Bogossian H; Milberg P; Eckardt L
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 28039911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome.
    Morita H; Kusano-Fukushima K; Nagase S; Fujimoto Y; Hisamatsu K; Fujio H; Haraoka K; Kobayashi M; Morita ST; Nakamura K; Emori T; Matsubara H; Hina K; Kita T; Fukatani M; Ohe T
    J Am Coll Cardiol; 2002 Oct; 40(8):1437-44. PubMed ID: 12392834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031.
    Inoue H; Yamashita T; Usui M; Nozaki A; Sugimoto T
    Cardiovasc Res; 1991 Mar; 25(3):223-9. PubMed ID: 1903082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.